NEO-811

· Neomorph, Inc

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NEO-811, covering 2026-03-11 to 2026-03-11. Get the full timeline:

Most recent: Clinical Trial Update: Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma [Phase 1]

See pricing